- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Cereno Scientific announces that the registration of warrants and convertibles to Fenja and Arena has been completed and that delivery of the warrants has been initiated | 1 | Cision News | ||
| Mo | New preclinical data for Cereno Scientific's novel IP Receptor Agonist CS585 presented at the ASH Annual Meeting and Exposition 2024 | 1 | Cision News | ||
| 13.12. | Cereno Scientific to present and engage in partnering and investor meetings at Biotech Showcase 2025 during J.P. Morgan Healthcare Week in San Francisco | 3 | Cision News | ||
| 06.12. | Cereno Scientific to present preclinical data for drug candidate CS585 at the ASH Annual Meeting and Exposition 2024 | 1 | Cision News | ||
| 29.11. | Cereno Scientific reports insider share purchases | 1 | Cision News | ||
| CERENO SCIENTIFIC Aktie jetzt für 0€ handeln | |||||
| 28.11. | Edison Investment Research publishes an updated research note of Cereno Scientific and an executive CEO interview with Sten R. Sörensen | 2 | Cision News | ||
| 28.11. | Cereno Scientific - A productive period with plenty more to come | 192 | Edison Investment Research | Cereno Scientific has released its Q324 results, marking a productive and strategically significant period. Following the positive top-line data from the Phase IIa safety study of CS1 in pulmonary arterial... ► Artikel lesen | |
| 26.11. | Cereno Scientific releases BioStock article highlighting Q3 Report 2024 | 2 | Cision News | ||
| 26.11. | CERENO SCIENTIFIC: Impactful third quarter for Cereno | 1 | Cision News | ||
| 21.11. | New preclinical data for Cereno Scientific's novel IP Receptor Agonist CS585 presented at the AHA Scientific Sessions 2024 | 2 | Cision News | ||
| 21.11. | Cereno Scientific AB: Cereno Scientific publishes the interim report for Q3 2024 (July 1-September 30) | 98 | GlobeNewswire (Europe) | The Board and Chief Executive Officer of Cereno Scientific AB here present the interim report for Q3 2024 (July 1-September 30).
Summary of the interim report for Q3 2024 (July 1-September 30)
Cereno... ► Artikel lesen | |
| 14.11. | CERENO SCIENTIFIC: BioStock has published an interview with CEO Sten R. Sörensen on the minimum 250 MSEK loan financing | 3 | Cision News | ||
| 13.11. | Preclinical data for Cereno Scientific's novel IP Receptor Agonist CS585 presented at ESC Congress 2024, now published in European Heart Journal | 1 | Cision News | ||
| 12.11. | Cereno Scientific - New SEK250m financing secures runway into 2026 | 207 | Edison Investment Research | Cereno Scientific has announced a new financing arrangement of at least SEK250m, with net proceeds expected to extend the runway into 2026, past several key clinical milestones. Secured from Fenja Capital... ► Artikel lesen | |
| 11.11. | Cereno Scientific secures minimum 250 MSEK loan financing to reach set milestones into 2026 | 1 | Cision News | ||
| 06.11. | Cereno Scientific's CEO on novel therapies for rare diseases | 1 | Cision News | ||
| 31.10. | Cereno Scientific participates at DNB Nordic Healthcare Conference 2024 | 2 | Cision News | ||
| 30.10. | Cereno Scientific presents at BioStock Life Science Summit 2024 | 1 | Cision News | ||
| 25.10. | Edison Investment Research increases valuation of Cereno Scientific to 4.05 BSEK or SEK 14.3 SEK/share after IPF selected as initial target indication for CS014 | 2 | Cision News | ||
| 25.10. | Cereno Scientific - CMD highlights a 'rare' portfolio refocus | 248 | Edison Investment Research | Cereno Scientific recently held a capital markets day (CMD), providing greater insight on its development pipeline and strategic objectives. The key takeaway was its decision to focus on the rare disease... ► Artikel lesen |
Seite:
1 2 3 4 Weiter >>
65 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ADMA BIOLOGICS | 17,400 | -2,68 % | ADMA Biologics, Inc.: ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility | ||
| QIAGEN | 42,900 | +0,04 % | Sartorius, Qiagen, Siemens Energy, DHL Group, Adidas, Puma: DAX-Ausblick | Nach seiner jüngsten Rekordjagd hat der DAX in der abgelaufenen Woche etwas Luft geholt. Unter dem Strich legte das größte deutsche Börsenbarometer trotzdem 21 Punkte zu und schloss mit knapp 20.406... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 76,52 | +5,05 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome | Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,990 | +6,24 % | Arcutis Biotherapeutics, Inc.: Arcutis Submits ZORYVE (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis | ZORYVE cream 0.05% provided meaningful disease clearance and rapid reduction in itch in pivotal trialsRoflumilast cream was well tolerated and demonstrated a favorable safety and tolerability profile... ► Artikel lesen | |
| EVOTEC | 8,405 | +1,08 % | CompuGroup, Evotec, Kion Group, Nagarro, ProSiebenSat.1 Media, TUI u.a. - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 7,340 | -0,27 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| CELCUITY | 12,460 | +3,83 % | Celcuity Inc.: Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium | Median overall survival (OS) among patients with HR+, HER2- advanced breast cancer who were treatment-naïve in the advanced setting was 77.3 months Median OS among patients previously treated with... ► Artikel lesen | |
| CONTINEUM THERAPEUTICS | 13,500 | +1,12 % | Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that... ► Artikel lesen | |
| BIONTECH | 108,60 | +0,09 % | Abstieg und Hoffnung: So steht es um den BioNTech-Konkurrenten Moderna | Die Aktie von Moderna hat in den vergangenen zwölf Monaten eine enttäuschende Entwicklung hingelegt. Im Nasdaq 100 gehört sie in diesem Zeitraum zu den zwei schlechtesten Werten. Nun muss sie den Index... ► Artikel lesen | |
| HUMACYTE | 4,635 | +33,77 % | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen | |
| AMGEN | 252,90 | +0,18 % | What's Going On With Amgen Stock On Friday? | ||
| JANUX THERAPEUTICS | 56,70 | -0,09 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| FOGHORN THERAPEUTICS | 5,140 | +3,21 % | Foghorn Therapeutics, Inc.: Foghorn Therapeutics Provides Update on FHD-286 Clinical Development Program and Strategic Priorities | Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy... ► Artikel lesen | |
| IMMUNOVANT | 25,880 | +0,86 % | Immunovant (NASDAQ:IMVT) Trading Down 5.2% - Here's Why | ||
| RECURSION PHARMACEUTICALS | 6,035 | -0,90 % | Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. ("Recursion") (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug... ► Artikel lesen |
Das Unternehmen CERENO SCIENTIFIC AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,005 (-1,08 %) liegt der Kurs bei 0,439 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CERENO SCIENTIFIC AB finden Sie auf Wallstreet Online.
